Quantcast
Last updated on April 25, 2014 at 5:51 EDT

Latest Hematopoietic stem cell transplantation Stories

2014-01-24 13:29:22

Investigators at Johns Hopkins report they have developed human induced-pluripotent stem cells (iPSCs) capable of repairing damaged retinal vascular tissue in mice. The stem cells, derived from human umbilical cord-blood and coaxed into an embryonic-like state, were grown without the conventional use of viruses, which can mutate genes and initiate cancers, according to the scientists. Their safer method of growing the cells has drawn increased support among scientists, they say, and paves the...

2014-01-23 08:30:32

- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - JERUSALEM, Jan. 23, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell...

2014-01-21 08:25:53

The "Good Morning America" anchor continues her efforts to recruit volunteer bone marrow donors to the national Be The Match Registry® while stressing the importance of research. NEW YORK and LOS ANGELES and MINNEAPOLIS, Jan. 21, 2014 /PRNewswire-USNewswire/ -- Be The Match and Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), have teamed up on a new public service announcement (PSA) campaign featuring ABC's "Good Morning America" anchor Robin...

2014-01-13 08:26:47

Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan. 13, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has filed the necessary regulatory submissions to commence a Phase 1 trial for BL-8040, a novel treatment for the mobilization of stem cells from the bone...

artificial bone marrow
2014-01-12 04:47:45

Rebekah Eliason for redOrbit.com - Your Universe Online An exciting breakthrough is offering hope for the treatment of blood diseases such as leukemia using artificial bone marrow. Specialized cells, known as hematopoietic stem cells, located within bone marrow, continuously replace and supply new blood cells such as red blood cells and white blood cells. Traditionally a blood disease like leukemia is treated with bone marrow transplants that supply the patient with new hematopoietic...

2014-01-08 12:28:20

NEW YORK, Jan. 8, 2014 /PRNewswire/ -- Bone marrow transplants are a $1.3 billion market and the fastest-growing hospital procedure in the U.S. They are the only potential cure for many blood cancers such as acute myeloid leukemia (AML) in older patients. The procedure is technically called hematopoietic stem cell transplantation (HSCT) and can be either a bone marrow transplant (BMT) or transplant of blood stem cells isolated from peripheral blood (PBSC). In either case, it involves...

2013-12-20 08:26:06

NEW YORK, Dec. 20, 2013 /PRNewswire/ -- Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any decision is made. Below are four important questions to ask during a doctor's visit. * What is a bone marrow transplant? First, patients undergo chemotherapy and sometimes radiation to destroy their...

2013-12-19 16:27:59

Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelio(TM) (defibrotide), a treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation DUBLIN, Ireland and VILLA GUARDIA, Italy, Dec. 19, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A. (Nasdaq: GENT) today announced that they have entered into a definitive agreement pursuant to...

2013-12-19 08:28:10

FDNY Supporter Sets a Record as He "Swabs" in an Effort to Save a Life NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Delete Blood Cancer - the U.S. contingent of DKMS, the world's largest bone marrow center - announced today that it reached a record number of registered donors this past Saturday, December 14(th), at a special New York City donor drive in honor of two FDNY families. Zane Staab from the Tunnels to Towers Foundation became the four-millionth person to swab the inside of his...

2013-12-09 20:22:38

Four Presentations Including Results of Phase 2b Randomized, Open-Label Study of Lower Doses of Quizartinib in FLT3 ITD Positive Relapsed Refractory Acute Myeloid Leukemia (AML) Patients SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55(th) Annual ASH Conference in New...


Latest Hematopoietic stem cell transplantation Reference Libraries

Bone Marrow Transplantation (journal)
2012-06-04 20:00:41

Bone Marrow Transplantation is a peer-reviewed medical journal published monthly by Nature Publishing Group. As of May 2012, the editor-in-chief is J.M. Goldman (UK). The journal publishes high quality, original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation in humans. The broad scope of the journal thus encompasses topics such as stem cell biology, kinetics and cytokine control, transplantation immunology, HLA and matching...

More Articles (1 articles) »